Vector VestAdvertisement Vector VestAdvertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, Auger08, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 1/26/2015 6:08:27 AM - Followers: 637 - Board type: Free - Posts Today: 3


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#80409   Yeah, Except the Share Price ISN'T Going Down rumper 01/26/15 06:08:27 AM
#80408   Wonderful OCAT Scientific Papers, chuckanutman 01/26/15 01:25:44 AM
#80407   I agree. elysse1kittycat 01/26/15 12:30:56 AM
#80406   Every time i read this it reminds me chuckanutman 01/25/15 11:58:07 PM
#80405   Come on man you know the adverse side ddombrow 01/25/15 11:01:31 PM
#80404   Every penny stock tries to associate these small Gastrodamas 01/25/15 09:06:52 PM
#80403   Ball's in your cart. Do some more homework. farviewhill 01/25/15 08:41:19 PM
#80400   GE could care less about OCAT for all Captain Kirk 01/25/15 07:08:26 PM
#80399   GE likes OCAT..... very much.... *WINK*...... GE is Trader Joey 01/25/15 06:51:34 PM
#80398   HUH...WHAT???...... Really no ACTC IPO EVER?? HUH WHAT???? Trader Joey 01/25/15 06:43:19 PM
#80396   WebMD, LLC" spare us all please.... OCAT is Trader Joey 01/25/15 06:21:32 PM
#80395   They have not attracted any large, non-diltive or Trader Joey 01/25/15 06:13:22 PM
#80394   Are talking about Intellectual Property? I believe AyeEye 01/25/15 02:07:58 PM
#80392   You are right; however, I don't believe Ocata ddombrow 01/25/15 01:18:40 PM
#80391   http://www.mirror.co.uk/news/world-news/moved-tears-blind-mum-sees-5040676 ddombrow 01/25/15 01:07:32 PM
#80390   OCAT has done some amazing work. "study provides chuckanutman 01/25/15 12:58:00 PM
#80389   Quote: "Certainly worth 5 billion."??? Captain Kirk 01/25/15 12:53:55 PM
#80387   Certainly worth 5 billion. homeslice10 01/25/15 12:39:06 PM
#80386   What?? "$OCAT Dec 2 IPO $62 mil, Captain Kirk 01/25/15 12:09:48 PM
#80385   LOL! "It would not surprized me to see Captain Kirk 01/25/15 11:59:41 AM
#80384   No News is Good News, I'm Guessing rumper 01/25/15 11:04:59 AM
#80383   http://www.healthline.com/health-news/stem-cell-transplants-first-ms-treatment-r Gastrodamas 01/25/15 10:45:56 AM
#80382   It would not surprized me to see a homeslice10 01/25/15 12:16:34 AM
#80381   Poliwogg Medical Breakthroughs Index (PMBI)Rule Book lasers 01/25/15 12:12:19 AM
#80380   Factors considered by large investors that could potentially AyeEye 01/24/15 10:42:18 PM
#80379   I would like to know the answer to Jbuzzhal 01/24/15 10:39:18 PM
#80378   Sorry. farviewhill 01/24/15 08:28:46 PM
#80377   Post a link for the Poliwogg requirements from lasers 01/24/15 06:46:31 PM
#80376   Ocata is not on Polliwog's latest list of farviewhill 01/24/15 05:35:55 PM
#80375   $OCAT three active recruited RPE USA/UK trials are lasers 01/24/15 04:56:08 PM
#80374   Someone needs to go there or even Vegas, elysse1kittycat 01/24/15 04:47:48 PM
#80373   Let's go to the University of Iowa with AyeEye 01/24/15 04:25:52 PM
#80372   GUY3, I wasn't ignoring your question in post farviewhill 01/24/15 03:43:04 PM
#80371   NO for OCATA. farviewhill 01/24/15 02:19:23 PM
#80370   OCAT Does Not Inject ESCs Embryonic Stem Cells rumper 01/24/15 10:23:24 AM
#80369   Guy-I hope what you say comes true. elysse1kittycat 01/24/15 10:04:53 AM
#80368   elysse good morning. Constant state of limbo, uncertainty, guy3 01/24/15 09:04:04 AM
#80367   $OCAT Poliwogg Investment, Speculation or Real ? lasers 01/24/15 07:31:22 AM
#80366   Vericel, formerly Aastrom, in which Dr. Wotton is lasers 01/23/15 11:15:21 PM
#80365   I do not remember whether I met Dt.Minger north40000 01/23/15 10:07:13 PM
#80364   NO? "He is a fan of ACTC now OCAT" Captain Kirk 01/23/15 08:15:48 PM
#80363   North. Good memory ! cty 01/23/15 07:22:24 PM
#80362   As an investor for a long time, one elysse1kittycat 01/23/15 07:21:42 PM
#80361   Thanks chuck. Great point!! He cty 01/23/15 07:21:28 PM
#80359   Strangely OTC MMs Naked Shorts only 7.1K out lasers 01/23/15 07:12:25 PM
#80358   Ocata-Therapeutics,-Inc. OCAT formerly named Advanced-Cell-Technology ACTC These chuckanutman 01/23/15 06:09:23 PM
#80357   NEVER SAID: "GE Healthcare Chief Dr. Stephen Minger Captain Kirk 01/23/15 06:04:53 PM
#80356   Thanks chuck---I see I came close to remembering north40000 01/23/15 05:51:48 PM
#80355   GE Healthcare Chief Dr. Stephen Minger likes OCAT chuckanutman 01/23/15 05:40:39 PM
#80354   Re: "Wow, that's a new one one me? elllk 01/23/15 05:00:23 PM
PostSubject